Jason Mast

Jason Mast, a colleague from STAT, dives into the intricate world of gene therapy, spotlighting a father's inspiring quest for solutions to help his child. They discuss the significant hurdles in this field, from financial challenges to unique fundraising efforts by families. Meanwhile, the conversation touches on why pharmaceutical companies remain silent on Robert F. Kennedy Jr.'s criticisms, exploring the broader implications for health policy. The emotional journey of families navigating rare conditions sheds light on the urgent need for effective therapies.

Lizzy Lawrence, a STAT reporter, gives us an inside look at the current turmoil at the FDA, detailing the chaos of frequent staffing changes and its impact on morale. Jason Mast then discusses the acquisition of Bluebird Bio, shedding light on the company's challenges in gene therapy and its drastic fall from grace. The conversation also touches on the rise of new biotech VCs, fueled by technological advancements and the pandemic, setting the stage for a dynamic shift in the industry.

Jason Mast, a reporter for STAT, delves into the troubling downturn in the once-promising CRISPR gene editing field. The discussion highlights the challenges companies face amid market skepticism and compares CRISPR innovations with RNA therapies. The conversation also touches on RFK Jr.'s controversial views as a nominee for HHS secretary, alongside insights into recent pharma earnings that spotlight successes in obesity treatments and the approval of a groundbreaking non-opioid pain drug, revealing the complexities of today’s biotech landscape.